Megenox 160 mg (Tablet)
Unit Price: ৳ 90.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Megestrol acetate |
| Company | Acme laboratories ltd |
| Also available as |
Indications
- Palliative treatment of advanced carcinoma of the breast
- Palliative treatment of advanced carcinoma of the endometrium
- Treatment for anorexia in patients with Acquired Immunodeficiency Syndrome (AIDS)
- Treatment for cachexia in patients with Acquired Immunodeficiency Syndrome (AIDS)
- Treatment for unexplained significant weight loss in patients with Acquired Immunodeficiency Syndrome (AIDS) & cancer
Pharmacology
- Synthetic, antineoplastic and progestational drug
- Inhibition of pituitary gonadotrophin production
- Decrease in estrogen secretion
- Modifying the action of other steroid hormones
- Exerting a direct cytotoxic effect on tumor cells
- Estimates of plasma levels of Megestrol Acetate
- Peak plasma concentrations occur 2 to 3 hours after a single oral dose 160 mg tablets
- Plasma half-life of Megestrol Acetate is 33 to 38 hours
- Approximately 66% of administered dose is excreted in the urine
- Approximately 20% of administered dose is excreted in the feces
Dosage & Administration
- Tablet: Breast cancer - 160 mg/day
- Tablet: Endometrial carcinoma - 40-320 mg/day in divided doses
- Tablet: At least 2 months of continuous treatment is considered an adequate period for determining the efficacy of Megestrol
- Oral Suspension: The recommended adult initial dosage of Megestrol Oral Suspension is 800 mg/day (20 ml/day)
Interaction
- Possible interactions of Megenox with concomitant medications have not been investigated
- Estrogens and Progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods
- Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid
Contraindications
- History of hypersensitivity to Megestrol Acetate or any component of the formulation
- Known or suspected pregnancy
Side Effects
- Weight gain is a frequent side effect of Megenox
- Thromboembolic phenomena including thrombophlebitis and pulmonary embolism
- Glucocorticoid effects
- Nausea
- Dyspnea
- Tumor flare
- Hyperglycemia
- Glucose intolerance
- Alopecia
- Hypertension
- Carpal tunnel syndrome
- Mood changes
- Hot flashes
- Malaise
- Asthenia
- Lethargy
- Sweating
- Rash
Pregnancy & Lactation
- Pregnancy Category D
- The use of progestational agents during the first four months of pregnancy is not recommended
- Very small amounts (approximately 0.1%) are excreted in mother's milk
Precautions & Warnings
- Close surveillance is indicated for any patient treated for recurrent or metastatic cancer
- Use with caution in patients with a history of thromboembolic disease
- Exacerbation of preexisting diabetes with increased insulin requirements has been reported in association with the use of Megenox
Use in Special Populations
- Pediatric Use: Safety and effectiveness in pediatric patients have not been established
- Insufficient data from clinical studies of Megenox tablets are available for patients 65 years of age and older to determine whether they respond differently than younger patients
Overdose Effects
- No serious unexpected side effects have resulted from studies involving Megenox administered in dosages as high as 1600 mg/day
Storage Conditions
- Store in a cool (below 30°C) and dry place, away from light & moisture
- Keep all medicines out of reach of children